Lenexa, Kansas Clinical Trials

A listing of Lenexa, Kansas clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

lung non-small cell squamous carcinoma
stage iiia lung squamous cell carcinoma ajcc v7
squamous cell carcinoma of lung
pembrolizumab
stage ii lung squamous cell carcinoma ajcc v7
Saint Luke's South Hospital
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
Ultrasound Axillary Vein Access: Evaluation of Learning Curve for an Alternative Approach to Cardiac Device Implantation

The purpose of this study is to determine the learning curve associated with Ultrasound (US) guided axillary vein access for cardiac device implantation based on length of procedure among operators of various levels of experience and to assess the 30-day complication rate for patients undergoing US guided device placement versus …

University of Kansas Medical Center
 (9.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to …

refractory multiple myeloma
proteasome inhibitor
daratumumab
pomalidomide
measurable disease
University of Kansas Hospital
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +8 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

metastatic nsclc
measurable disease
pembrolizumab
anaplastic lymphoma
solid tumor
Univ Kansas Med Ctr /ID# 216897
 (9.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Multicenter Clinical Trial of a Phakic Implantable Collamer Lens (ICL)

This objective of this study is to evaluate the safety, and to collect supportive data on effectiveness of the EVO/EVO+ Visian Implantable Collamer Lens (ICL) in study participants who have a diagnosis of myopia or myopia with astigmatism. Primary study analysis will be evaluated when 300 primary eyes complete 6 …

myopia
severe myopia
astigmatism
Durrie Vision
 (2.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +13 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

glycogen storage disease type ii
gaa gene
myozyme
replacement therapy
deficiency
Investigational Site Number 840020
 (9.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

deficiency
replacement therapy
agalsidase beta
fabrazyme
fabry's disease
Investigational Site Number 840071
 (9.9 away) Contact site
  • 0 views
  • 05 Aug, 2024
  • +136 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

datscan
genetic testing
muscle rigidity
tremor
alpha-synuclein
University of Kansas Medical Center
 (9.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
Accuracy of TCOM vs NIRS in Predicting Wound Outcomes in Patients Treated With or Without Revascularization

The primary purpose of this project is to compare the accuracy of transcutaneous oxygen monitoring and near infrared spectroscopy in assessing cutaneous oxygen levels in chronic wounds of patients following revascularization procedures as well as those with conservatively managed chronic wounds. This study will also compare the efficiency and practicality …

near infrared spectroscopy
lower extremity wound
University of Kansas Medical Center
 (9.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Prospective Non-interventional Multinational Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to …

cancer
refractory multiple myeloma
isatuximab
complete resection
multiple myeloma
Investigational Site Number 8400016
 (7.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations